30 results
Thumbnail

D1.16 - Molecular sensitization profiles in house dust mite allergic patients from Valencian Community

Thumbnail

D1.18 - Comparative Analysis of Nasal Secretions and Serum Biomarkers in House Dust Mite Allergy: Correlation with Symptoms and Skin Prick Test Results

Thumbnail

D1.19 - Contribution of Panallergens to Edible Insect Reactivity in Mite-Sensitized Individuals

Thumbnail

D1.20 - Progesterone-Induced Urticaria: Diagnostic and Therapeutic Approach

Thumbnail

D1.22 - Molecular Allergen Sensitization Patterns in Cat, Dog and Horse Allergies in Children

Thumbnail

D1.23 - Unrestricted Potential: The Role of AMS in Tackling Allergy Labels

Thumbnail

D1.24 - Towards risk assessment of peanut sensitised patients based on statistical modelling of 32,500 IgE-macroarray test results

Thumbnail

D1.25 - Clinical Characteristics of Chronic Urticaria in Adults Under 45 Years Old with Vitamin D Insufficiency

Thumbnail

D2.167 - Effect of Metformin on allergen specific immunotherapy

Thumbnail

D2.169 - Association of Antenatal Corticosteroid Treatment with Risk of Allergic Diseases in Children

Thumbnail

D2.174 - Patient survey to determine the minimal clinically important difference for a combined symptom and medication score in grass AIT

Thumbnail

D2.179 - Evaluation of Sublingual Immunotherapy for Cat Allergy: Results from a Non-Interventional Study

Thumbnail

D2.168 - Systemic reactions to subcutaneous immunotherapy in children

Thumbnail

D2.170 - The placebo effect leads to significantly lower values regarding allergic symptoms and medication use in birch-pollen allergic patients during the birch pollen season

Thumbnail

D2.171 - The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment

Thumbnail

D2.172 - Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions

Thumbnail

D2.173 - Subcutaneous allergen-specific immunotherapies for inhalation allergens induce higher levels of therapy specific IgG4 antibodies than sublingual therapies: a retrospective data analysis

Thumbnail

D2.175 - TAPAS – non-inferiority of clinical effectiveness in children compared to adults: interim results of a long-term NIS

Thumbnail

D2.176 - Improved quality of life after PQ Grass in comparison to SLIT products in grass allergic patients

Thumbnail

D2.177 - The Efficacy of Sublingual Immunotherapy in Mild versus Moderate Atopic Dermatitis Among Children with House Dust Mite Allergic Rhinitis